Bristol Myers Squibb-Pfizer Alliance in collaboration with Fitbit to take on Apple Watch
Under Thursday's deal, the company's devices will carry software that will help detect atrial fibrillation - the most common type of irregular heartbeat - after approval from the U.S. Food and Drug Administration.
New Delhi: Fitbit Inc is developing a method to detect an irregular heart rhythm in time through a partnership with Bristol-Myers Squibb-Pfizer Alliance, as the wearable device maker looks to match a feature available on rival Apple Inc's Watch.
Fitbit has been pushing deeper into the healthcare space and in August tied up with the Singapore government to provide fitness trackers and services in a health program that the company said could reach up to one million users.
Read Also:-Bristol-Myers CEO says Japan restrictive drug price policies risk diverting investment
Under Thursday's deal, the company's devices will carry software that will help detect atrial fibrillation - the most common type of irregular heartbeat - after approval from the U.S. Food and Drug Administration.
Atrial fibrillation is a condition associated with irregular heart rhythm that increases the risk of stroke and is usually prevalent among people above 65 years of age.
Read Also:-Bristol-Myers blockbuster Opdivo fails to meet the goal of brain tumour study
About 2.7 million to 6 million people suffer from the condition in the United States, according to the Centre of Disease Control and Prevention.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd